Cargando…

Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list

PURPOSE: To assess the reporting quality of published economic evaluations of the negotiated oncology drugs listed for China’s 2020 National Reimbursement Drug List (NRDL). METHODS: A comprehensive search was conducted to identify economic evaluation studies of negotiated oncology drugs listed in Ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Liu, Jiang, Zhixin, Li, Fuming, Wei, Yan, Ming, Jian, Yang, Yi, Liu, Shimeng, Shi, Lizheng, Chen, Yingyao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719239/ https://www.ncbi.nlm.nih.gov/pubmed/36463141 http://dx.doi.org/10.1186/s12913-022-08858-7

Ejemplares similares

Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List
por: Liu, Wenbin, et al.
Publicado: (2019)

Reporting quality of economic evaluations of the negotiated Traditional Chinese Medicines in national reimbursement drug list of China: A systematic review
por: Yan, Juntao, et al.
Publicado: (2023)

How health technology reassessment can support disinvestment in China’s national drug reimbursement list
por: Shi, Lizheng, et al.
Publicado: (2023)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
por: Macabeo, Bérengère, et al.
Publicado: (2023)

Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study
por: Zhu, Hong, et al.
Publicado: (2022)

Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis
por: Yi, Hongbin, et al.
Publicado: (2023)

Critical Appraisal of Reimbursement List in Bosnia and Herzegovina
por: Mujkic, Sabina, et al.
Publicado: (2017)

Differences in reimbursement listing of anticancer therapies in China: an observational study
por: Guan, Xiaodong, et al.
Publicado: (2020)

Impact of delisting OTC medicines from reimbursement list
por: Chytilová, Petra, et al.
Publicado: (2015)

Preferred drug lists: Potential impact on healthcare economics
por: Ovsag, Kimberly, et al.
Publicado: (2008)

Budget Impact of Introducing Linagliptin into Bosnia and Herzegovina Health Insurance Drug Reimbursement List in 2016-2018
por: Catic, Tarik, et al.
Publicado: (2017)

Chinese Proprietary Herbal Medicine Listed in ‘China National Essential Drug List’ for Common Cold: A Systematic Literature Review
por: Chen, Wei, et al.
Publicado: (2014)

Using the WHO Essential Medicines List to Assess the Appropriateness of Insurance Coverage Decisions: A Case Study of the Croatian National Medicine Reimbursement List
por: Jeličić Kadić, Antonia, et al.
Publicado: (2014)

Price-Cutting Trends in New Drugs after Listing in South Korea: The Effect of the Reimbursement Review Pathway on Price Reduction
por: Kim, Sungju, et al.
Publicado: (2020)

Pricing and reimbursement of novel oncology drugs in Sweden
por: Haglund, Mattias, et al.
Publicado: (2014)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
por: Zhu, Xingyue, et al.
Publicado: (2023)

Commentary: “To list, or not to list? That is the question”
por: Chen, Jing Yu, et al.
Publicado: (2021)

Physicians’ Visiting List List
Publicado: (1875)

Mathews’ List of Drugs, Chemicals, Etc., and Price Current
Publicado: (1859)

List of abbreviations: Liste des abréviations
por: Mandelbrojt-Sweeney, Mireille, et al.
Publicado: (2019)

Assessment of Methodological Quality of Economic Evaluations in Belgian Drug Reimbursement Applications
por: Simoens, Steven
Publicado: (2013)

Inclusion of nicotine replacement therapy in the national essential drug list in India: Benediction for tobacco quitters?
por: Satpathy, Nancy, et al.
Publicado: (2022)

The evolution of Taiwan’s National Health Insurance drug reimbursement scheme
por: Hsu, Jason C, et al.
Publicado: (2015)

Examining the association between oncology drug clinical benefit and the time to public reimbursement
por: Thomson, Sasha, et al.
Publicado: (2021)

Changes in Drug List Prices and Amounts Paid by Patients and Insurers
por: Yang, Eric J., et al.
Publicado: (2020)

The influence of Medicare Part D on the list pricing of brand drugs
por: Ippolito, Benedic N., et al.
Publicado: (2023)

A Universal Pharmacological-Based List of Drugs with Anticholinergic Activity
por: Lavrador, Marta, et al.
Publicado: (2023)

Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China
por: Mingge, Xia, et al.
Publicado: (2023)

Analyzing the innovation ability of listed companies in the core area of the Huaihai economic zone
por: Liu, Qin-Xia
Publicado: (2023)

A comparative analysis of the Libyan national essential medicines list and the WHO model list of essential medicines
por: Mustafa, Asma Abubakr, et al.
Publicado: (2010)

Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey
por: Liu, Shimeng, et al.
Publicado: (2023)

A list of things one could do better or faster if the scrapers were controlled by computer
por: Keil, Eberhard
Publicado: (1973)

Health Technology Reassessment: Addressing Uncertainty in Economic Evaluations of Oncology Drugs at Time of Reimbursement Using Long-Term Clinical Trial Data
por: Ball, Graeme, et al.
Publicado: (2023)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2020)

Price trends of reimbursed oncological drugs in Switzerland in 2005–2019: A descriptive analysis
por: Rachamin, Yael, et al.
Publicado: (2021)

Primary care physicians report high trust in and usefulness of the Stockholm drug and therapeutic committee’s list of recommended essential medicines (the ‘Wise List’)
por: Eriksen, Jaran, et al.
Publicado: (2017)

Data of pre-IPO or listing firm characteristics and post-listing stock returns of Chinese listed firms
por: Li, Hong
Publicado: (2020)

Classification of Drugs Listed in Iranian Pharmacopoeia Based on Impact on Driving Performance
por: Farahbakhsh, Mostafa, et al.
Publicado: (2019)

The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication
por: Frois, Christian, et al.
Publicado: (2013)

List of benefits
por: CERN, Health Insurance Scheme
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l0odiv2afjrl27k6r6q95r4q4g